A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID
Latest Information Update: 26 Jul 2022
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NILOdeepR
- Sponsors Novartis; Novartis Pharmaceuticals
Most Recent Events
- 07 Apr 2021 Status changed from active, no longer recruiting to completed.
- 07 Sep 2020 Planned End Date changed from 22 Feb 2021 to 20 Mar 2021.
- 06 Jan 2020 Status changed from recruiting to active, no longer recruiting.